Va
Non verificato

Vasomune Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza
05/10/2026
Industria
Scienza
Sanità
Farmaceutica
Medicina - Varie
Cardiologia
Chimica
Biotecnologia
Salute
Vasomune Therapeutics Receives Funding Assistance to Advance Its Dual-Use Vascular Leak Therapy
1.00
28/09/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pneumonia/ARDS
1.00
27/07/2026
Eventi
Industria
Scienza
Medicina - Varie
Cardiologia
Biotecnologia
Farmaceutica
Salute
Difesa / Forze Armate
Vasomune Therapeutics to Present on Pegevongitide Therapeutic Capability at the 2026 NATO NSPA CBRN
1.00
21/07/2026
Scienza
Cardiologia
Biotecnologia
Difesa / Forze Armate
Farmaceutica
Salute
Eventi
Industria
Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium
1.00
03/09/2025
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato del lavoro
Industria
Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients
1.00
03/12/2024
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Cardiologia
Biotecnologia
Sanità
Salute
Farmaceutica
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort for AV001-004 Phase 2a Study
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0